Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Operating Leases (2021 - 2025)

Senti Biosciences has reported Operating Leases over the past 5 years, most recently at $28.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $28.9 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $28.9 million (changed 0.0% YoY), and the annual figure for FY2025 was $28.9 million, changed 0.0%.
  • Operating Leases for Q4 2025 was $28.9 million at Senti Biosciences, down from $30.1 million in the prior quarter.
  • Over the last five years, Operating Leases for SNTI hit a ceiling of $36.6 million in Q1 2024 and a floor of $21.0 million in Q4 2021.
  • Median Operating Leases over the past 5 years was $33.0 million (2023), compared with a mean of $32.2 million.
  • Biggest five-year swings in Operating Leases: surged 67.25% in 2022 and later fell 13.86% in 2024.
  • Senti Biosciences' Operating Leases stood at $21.0 million in 2021, then skyrocketed by 67.25% to $35.1 million in 2022, then fell by 4.46% to $33.5 million in 2023, then dropped by 13.86% to $28.9 million in 2024, then changed by 0.0% to $28.9 million in 2025.
  • The last three reported values for Operating Leases were $28.9 million (Q4 2025), $30.1 million (Q3 2025), and $31.3 million (Q2 2025) per Business Quant data.